William L Macias

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. pmc Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome
    Andrew F Shorr
    Department of Medicine, Section of Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA
    Crit Care 10:R92. 2006
  2. pmc Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:R607-22. 2005
  3. ncbi request reprint Severe protein C deficiency predicts early death in severe sepsis
    William L Macias
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Crit Care Med 32:S223-8. 2004
  4. doi request reprint Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy
    Jeffrey S Riesmeyer
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 52:789-97. 2012
  5. ncbi request reprint Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis
    William L Macias
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Crit Care Med 32:2385-91. 2004
  6. ncbi request reprint The value of innovation
    William L Macias
    Lilly Research Laboratories, Indianapolis, USA
    S Afr Med J 93:502-3. 2003
  7. pmc New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:S38-45. 2005
  8. ncbi request reprint Activated protein C and acute kidney injury: Selective targeting of PAR-1
    Akanksha Gupta
    Lilly Research Laboratories, IN 46285 0444, USA
    Curr Drug Targets 10:1212-26. 2009
  9. ncbi request reprint Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
    William L Macias
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA
    Clin Pharmacol Ther 72:391-402. 2002
  10. doi request reprint Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38
    Rebecca E Wrishko
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 49:984-98. 2009

Collaborators

Detail Information

Publications23

  1. pmc Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome
    Andrew F Shorr
    Department of Medicine, Section of Pulmonary and Critical Care Medicine, Washington Hospital Center, Washington, DC, USA
    Crit Care 10:R92. 2006
    ..The objective of this study was to determine whether early directional changes in protein C levels correlate with outcome...
  2. pmc Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:R607-22. 2005
    ..Such an interaction might warrant a change in the assumptions that underlie current trial designs...
  3. ncbi request reprint Severe protein C deficiency predicts early death in severe sepsis
    William L Macias
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Crit Care Med 32:S223-8. 2004
    ..To explore the relationship between measures of baseline disease severity and survival time in patients with severe sepsis...
  4. doi request reprint Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy
    Jeffrey S Riesmeyer
    Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    J Clin Pharmacol 52:789-97. 2012
    ....
  5. ncbi request reprint Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis
    William L Macias
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
    Crit Care Med 32:2385-91. 2004
    ..To elucidate sources of variability in the estimate of treatment effects in a successful phase 3 trial in severe sepsis and to assess their implications on the design of future clinical trials...
  6. ncbi request reprint The value of innovation
    William L Macias
    Lilly Research Laboratories, Indianapolis, USA
    S Afr Med J 93:502-3. 2003
  7. pmc New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated)
    William L Macias
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Crit Care 9:S38-45. 2005
    ..This article discusses the way in which the interactions of APC may alter the microcirculation...
  8. ncbi request reprint Activated protein C and acute kidney injury: Selective targeting of PAR-1
    Akanksha Gupta
    Lilly Research Laboratories, IN 46285 0444, USA
    Curr Drug Targets 10:1212-26. 2009
    ..The focus of this review will be to summarize the emerging data suggesting the potential therapeutic benefit of APC and related members of the pathway in the prevention and treatment of acute kidney injury...
  9. ncbi request reprint Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis
    William L Macias
    Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Ind 46285, USA
    Clin Pharmacol Ther 72:391-402. 2002
    ..We aimed to characterize the pharmacokinetics and pharmacodynamics of drotrecogin alfa (activated) (recombinant human activated protein C) in patients with severe sepsis...
  10. doi request reprint Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38
    Rebecca E Wrishko
    Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
    J Clin Pharmacol 49:984-98. 2009
    ..1%) was 30% (90% confidence interval [CI] 1.16-1.45) higher than exposure in patients > or =60 kg. Mean Pras-AM exposures for patients > or =75 years (10.5%) were 19% (90% CI: 1.11-1.28) higher compared with patients <75 years...
  11. ncbi request reprint Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure
    Jean Francois Dhainaut
    Department of Intensive Care, Cochin Hospital, AP HP, Cochin Institute, Cochin Port Royal Medical School, Paris V University, Paris, France
    Crit Care Med 33:341-8. 2005
    ..To determine whether changes in coagulation biomarkers during the first day of severe sepsis correlate with progression from single to multiple organ failure and subsequent death...
  12. ncbi request reprint Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis
    E Wesley Ely
    Division of Allergy, Pulmonary and Critical Care Medicine, Tennessee Valley Veteran s Affairs Geriatric Research Education and Clinical Center, Vanderbilt University School of Medicine, Nashville 37232 8300, USA
    Crit Care Med 31:12-9. 2003
    ....
  13. pmc Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock
    Hector R Wong
    Division of Critical Care Medicine, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229 3039, USA
    Am J Respir Crit Care Med 178:276-82. 2008
    ..Interventional clinical trials involving children with septic shock would benefit from an efficient preenrollment stratification strategy...
  14. ncbi request reprint Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis
    Lakhmir S Chawla
    Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC 20037, USA
    Clin J Am Soc Nephrol 2:22-30. 2007
    ..IL-6 data and the absence of correlation with measures of hypotension (e.g., mean arterial pressure, dosage of vasopressors) support the notion that inflammation is a significant component of AKI in SS...
  15. ncbi request reprint Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)
    Marcel Levi
    Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Am J Respir Crit Care Med 176:483-90. 2007
    ..Biological plausibility exists for heparin to reduce DrotAA efficacy and/or increase bleeding...
  16. ncbi request reprint Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial
    Simon Nadel
    St Mary s Hospital and Imperial College, London, UK
    Lancet 369:836-43. 2007
    ..We initiated the RESOLVE (REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspectiVE) trial to investigate the efficacy and safety of the drug in children...
  17. pmc Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
    Gordon R Bernard
    Division of Allergy, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Crit Care 7:155-63. 2003
    ....
  18. ncbi request reprint Activated protein C: do more survive?
    William L Macias
    Intensive Care Med 32:605-7; author reply 610-2. 2006
  19. ncbi request reprint Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis
    Phil Barton
    Department of Pediatrics, Division of Pediatric Critical Care, Children s Hospital at Saint Francis, Tulsa, Oklahoma, USA
    Pediatrics 113:7-17. 2004
    ..We have now performed a preliminary analysis of the safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in pediatric patients with severe sepsis...
  20. ncbi request reprint Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
    Edward Abraham
    Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 353:1332-41. 2005
    ..The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death...
  21. ncbi request reprint Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever
    Lisa E Hensley
    Virology Division, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    J Infect Dis 196:S390-9. 2007
    ..The aim of this study was to test the efficacy of rhAPC as a potential treatment for ZHF...
  22. ncbi request reprint A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis
    William L Macias
    Shock 20:582-3; author reply 583-4. 2003
  23. ncbi request reprint Early changes in organ function predict eventual survival in severe sepsis
    Mitchell M Levy
    Brown University School of Medicine, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
    Crit Care Med 33:2194-201. 2005
    ..We hypothesized that a risk prediction model based on early (baseline to day 1 of study) response to standard care should be significantly related to 28-day survival...